318 results on '"Strupp C"'
Search Results
2. Assessing in vitro dermal absorption of dry residues of agrochemical sprays using human skin within OECD TG 428
3. P22-27: Toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors: converging evidence from in vivo and a new approach method invitrothat mouse is the most relevant test species
4. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML
5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
6. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
7. Assessment of an extended dataset of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption
8. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
9. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
10. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
11. P08-18 Predicting non-genotoxic carcinogenic potential of agrochemicals: a mechanistic approach
12. Assessment of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption
13. P772: PROGNOSTIC IMPACT OF DISEASE-RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)
14. P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY
15. Validation of the IPSS and Other Scoring Systems in Patients with Primary MDS
16. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification
17. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
18. Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma
19. Vertebral fractures in multiple myeloma: first results of assessment of fracture risk using dynamic contrast-enhanced magnetic resonance imaging
20. Thalidomide for the treatment of patients with myelodysplastic syndromes
21. Independent validation of the MDS comorbidity score (MDS-CI): V956
22. Prognostic Factors and their Relevance in Different Subgroups of Myelodysplastic Syndromes - An Analysis of 2553 Patients from the Düsseldorf MDS Registry: V373
23. Isolated der (1;7) fits well in the intermediate risk group of the cytogenetic scoring system for myelodysplastic syndromes
24. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
25. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome
26. Treatment of Acute Myeloid Leukemia with Valproic Acid Alone or in Combination with All-trans-Retinoic Acid: O392
27. Therapy-Related Myelodysplastic Syndromes: Characteristics in a Consecutive Series of 121 Patients: O358
28. Valproic Acid Alone or in Combination with All-trans-Retinoic Acid (ATRA) for the Treatment of Myelodysplastic Syndromes: O357
29. Thalidomide for the treatment of idiopathic myelofibrosis
30. Bone marrow microcirculation analysis by dynamic contrast-enhanced MR imaging in patients with myelodysplastic syndromes during thalidomide: P674
31. Cytogenetic response to thalidomide treatment in three patients with MDS: P680
32. Treatment of the 5q-syndorme with all-trans-retinoic acid: A phase II study of the German MDS study group: P667
33. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid: P668
34. Low-dose cytarabine cyclical maintenance in the 5q-syndrome: A case report: P666
35. No evidence of increasing incidence of myelodysplastic syndromes: V415
36. Transcription profile of hematopoietic CD34+ cells from patients with myelodysplastic syndrome: 912
37. Thalidomide for the treatment of myelodysplastic syndromes (MDS): 234
38. How to identify very-low-risk patients with myelodysplastic syndromes (MDS): 223
39. Response to combination therapy with valproic acid and alltrans retinoic acid in a patient with sAML/MDS: 228
40. Thalidomide for the treatment of osteomyelofibrosis: 88
41. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells
42. Monarchie und nationale Einheit:Eine neue Biographie über Königin Wilhelmina
43. Kulturgeschichte und Kulturkritik. Neue niederländische Literatur zu Johan Huizinga
44. P124 Matched pair analysis of conventional regimens versus hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes – an analysis from the Duesseldorf MDS Registry
45. P009 Incidence and prevalence of myelodysplastic syndromes (MDS) in Duesseldorf 1996–2005
46. C007 Validation of the WHO proposals for the classification of unclassifiable myelodysplastic syndromes
47. C004 Relevance of prognostic factors in different subgroups of myelodysplastic syndromes
48. C006 Detailed morphologic findings in 2773 patients with myelodysplastic syndromes
49. A human relevance investigation of PPARα-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats
50. Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.